Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses using topical Calcipotriol and Valproic Acid for hair loss, focusing on their mechanisms involving the VDR receptor and Wnt/beta-catenin pathway. Specific treatments mentioned are Minoxidil, Finasteride, and RU58841.

Veradermics is a promising new treatment for hair loss, essentially a repackaged version of Minoxidil. The user is optimistic about its potential effectiveness.

Doctors are testing verteporfin topically for healing and potential regeneration after transplants. The user is asking how it is formulated for topical use, such as if it's mixed with a carrier gel.

A user is seeking advice on treating a chin scar with Verteporfin, noting that higher doses were more effective. Another user responds that they do not use it, without providing further explanation.

A participant using Veradermics VDPHL01, an extended-release oral minoxidil, experienced significant hair regrowth from Norwood 6 to Norwood 3V without side effects. They plan to use dutasteride after the treatment to maintain results.

The conversation is about the FDA approval of WINLEVI for acne treatment and the anticipation of Breezula, a hair loss treatment using the same active ingredient, which may indicate a positive future for Breezula's release. There is disappointment that Breezula's results are not optimal, but it is seen as progress in hair loss treatment.

A user experienced significant hair regrowth from Xeljanz after severe alopecia but can no longer afford it. They are seeking ways to obtain the medication despite its high cost and potential side effects.

Exploring the potential of using Verteporfin to grow follicles in combination with microneedling, as well as the cost of administering a single injection and the possibility of combining it with minoxidil.

The acne medication Winlevi, which contains Clascoterone, is available in the U.S. and may slow down hair loss until a higher concentration treatment, Breezula, is released.

The potential of using Verteporfin to prevent hair loss scars and possible regrowth, with two doctors currently testing it, although the price of a 15mg bottle is expensive.

The conversation is about finding a clearnet vendor for clascoterone, also known as Winlevi, for hair loss treatment. The user is seeking recommendations via direct message.

The conversation discusses using verteporfin for hair regrowth and minimizing scarring after hair transplants. Some individuals plan to self-administer verteporfin, potentially in combination with microneedling, as an alternative to hair transplants.

Veradermics' phase 2 trial of slow-release oral minoxidil shows promising hair regrowth with minimized side effects, gaining significant attention and funding. PP405 is also noted for its potential as a side-effect-free alternative.

The conversation is about using topical valproic acid (VPA) for hair loss, focusing on its application method, usage frequency, and combination with other treatments like micro-needling. No specific experiences with VPA were shared.

Veradermics' oral minoxidil shows promise for hair regrowth, with some users reporting significant improvements, while Pelage's PP405 results are less convincing and lack transparency. There is skepticism about both treatments' long-term effectiveness and potential side effects.

Veradermics' new hair loss treatment, VDPHL01, is likely a modified release oral minoxidil, which has received $75 million in funding for clinical trials. Despite skepticism about investing in a known treatment, some believe it could offer improved efficacy and reduced side effects.

User seeks participants for Verteporfin group buy. Verteporfin, FDA approved, may regenerate hair follicles and sweat glands through heavy microneedling.

The conversation discusses the potential of Verteporfin, an FDA-approved drug, for hair loss treatment, particularly in combination with microneedling or PRP. Users express hope and curiosity about its application, while some remain cautious due to the need for more extensive testing.

The conversation discusses disappointment in Verteporfin for hair loss treatment, with a mention of an upcoming trial by Dr. Bisanga. No specific treatments were confirmed as used by the original poster.

Clascoterone cream was submitted for review to Health Canada in August 2022, with hopes of approval within 3-6 months. It may potentially enhance finasteride's effects for hair loss treatment.

Winlevi (clascoterone 1%) is being discussed as a potential hair loss treatment. Users are considering its use despite concerns about its delivery method.

The conversation is about the approval of Clascoterone (Winlevi) in Canada for hair loss treatment. One user expressed skepticism about its effectiveness due to low concentration.

Clascoterone is a topical treatment for androgenetic alopecia, showing modest to moderate hair regrowth, and may be available by 2027-2028. It is considered safer than finasteride, with discussions on its effectiveness compared to RU58841 and pyrilutamide.

The user is considering using CB or clascoterone for hair loss, potentially as an alternative to RU. They're also contemplating asking a dermatologist for topical clascoterone cream to apply to their temple.

The conversation discusses the potential use of verteporfin for hair loss treatment, with one user mentioning their surgeon's interest in trying it and another noting its research status and clinical use as a YAP inhibitor. Some users debate the market size, availability of generics, and the optimism in the hair loss community regarding new treatments.

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

User seeks availability of Breezula and its delayed trials. Asks for success with similar topical antiandrogens like fluridil.

A user was prescribed betamethasone dipropionate spray for a receding hairline, which caused skin peeling and depigmentation. They stopped using it and are considering alternatives like BPC-157/TB-500 for healing.

A human trial of verteporfin, a drug that can inhibit wound healing by scarring and promote regeneration of original tissue and hair follicles to provide an unlimited source for hair transplants; people discussed the potential of this drug and how it could be rolled out in mainstream with more doctors getting on board.

The conversation discusses the potential release of Winlevi in 2019 by Cassiopeia for hair loss treatment. It suggests a regimen combining minoxidil, Winlevi, Nizoral, and possibly dermarolling, with a comment mentioning Breezula as an alternative to finasteride without side effects.